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Peripartumcardiomyopathy(PPCM)isararebutpotentiallylethalcomplicationofpregnancyoccurringinapproximately1:3,000
live births in the United States although some series report a much higher incidence. African-American women are particularly at
risk. Diagnosis requires symptoms of heart failure in the last month of pregnancy or within ﬁve months of delivery in the absence
of recognized cardiac disease prior to pregnancy as well as objective evidence of left ventricular systolic dysfunction. This paper
provides an updated, comprehensive review of PPCM, including emerging insights into the etiology of this disorder as well as
current treatment options.
1.Introduction
Peripartum cardiomyopathy, the development of systolic
heart failure in the puerperium, is a rare but serious
complication of pregnancy. Diagnosis requires objective
evidence of left ventricular (LV) dysfunction with no other
explanation for heart failure signs and symptoms [1, 2].
In the United States, the best estimate of incidence of
peripartum cardiomyopathy (PPCM) is 1:3,000 live births
[3]. While half of the women aﬀected by this disorder
recover LV function, the other half suﬀer signiﬁcant mor-
bidity and mortality [4]. The etiology of PPCM remains
unclear, contributing to the poor outcomes seen in women
aﬀected by the disorder, as targeted treatment is not yet
available.
2. Incidence
The incidence of PPCM in the United States is diﬃcult to
estimate as overlapping diagnosis codes make chart review
both tedious and potentially inaccurate. Until recently, only
small studies reporting the experience of single centers were
available to estimate the incidence of this rate disorder.
Two large studies in the United States reviewed ICD-9
c o d e sa n dp e r f o r m e dc h a r tr e v i e w st ob e t t e rr e p o r ta n
estimate of incidence. Charts from discharges from the
National Hospital Discharge Survey database (1990–2002)
were reviewed to identify cases of PPCM. This study
reported an estimated incidence of 1:3,189 live births in
the US with the highest incidence occurring in African-
American women [3]. A similar study examined ICD-9
codes within the database of the Kaiser Permanent health
systeminsouthernCaliforniafrom1996–2005andestimated
an incidence of 1:4025 live births, again reporting the
highest incidence in African-American women [5]. This
study, however, had a high percentage of Hispanic women,
the ethnicity with the lowest incidence of PPCM. Finally,
a recent case-control study found an incidence of approx-
imately 1:540 which was higher than that reported in
other US series but comparable to that reported in African
countries [6].
3. Risk Factors
The strongest risk factor for PPCM appears to be African-
American ethnicity (OR 15.7; CI 3.5–70.6) [6]. Other
reported risk factors include age, pregnancy-induced hyper-
tension or preeclampsia [3], multiparity, multiple gestations,
obesity, chronic hypertension, and the prolonged use of
tocolytics [7].2 Journal of Pregnancy
4.Diagnosis
TheNationalHeart,LungandBloodInstitute(NHLBI),with
theNationalInstitutesofHealth(NIH),publisheddiagnostic
criteria for PPCM to direct more accurate research on
epidemiology, pathophysiology, and outcomes. The criteria
include: (1) onset of heart failure signs and symptoms in the
last month of pregnancy or within 5 months postpartum; (2)
LV systolic dysfunction with ejection fraction (EF) measured
≤45% or LV end diastolic dimension ≥2.7cm/m2;( 3 )n o
evidence of pre-existing heart disease prior to peripartum
symptomonset; (4) no other identiﬁable causes of heart
failure [1]. Use of these criteria should prevent the inclusion
of women with undiagnosed but pre-existing heart disease
unmasked by the hemodynamic eﬀects of pregnancy, as
these women should present with signs and symptoms of
heart failure in the second trimester when the hemodynamic
stress of pregnancy peaks [8]. However, Elkayam et al.
described women presenting with heart failure earlier in
pregnancy with similar clinical courses and outcomes as
women meeting the established diagnostic criteria [9]. An
objective measurement of LV function excludes women with
normal cardiac function with postpartum volume overload,
which is common due to normal physiologic changes of
pregnancy. Finally, PPCM is a diagnosis of exclusion [10]
as many peripartum complications may result in depressed
cardiac function, including infection, pulmonary embolism,
and myocardial ischemia.
5.ClinicalFindings
The clinical presentation of PPCM is most often dyspnea
(90%),tachycardia(62%),andedema(60%)[11].Somecase
studies also cite unusual presentations, including multiple
thromboembolic events [12] and acute hypoxia [13]. Onset
occurs one month prior to delivery and up to ﬁve months
after delivery. However, the majority of women present
postpartum. The most common clinical presentation (dys-
pnea, tachycardia, and edema) can be mistaken for another
disorder, such as pneumonia or depression. Therefore, when
a woman presents in the puerperium with these ﬁndings, an
echocardiogram should be considered.
Cardiacbiomarkers,includingB-typenatriureticpeptide
(BNP), are elevated in patients presenting with PPCM
although these markers are not unique to PPCM. Elevations
of troponin T (TnT) appear to have prognostic signiﬁcance
in this group. A TnT level ≥0.04ng/mL at presentation
predicts persistence of systolic dysfunction with a sensitivity
of 55% and speciﬁcity of 91% [14]. Inﬂammatory cytokines
(IL-2, TNFα and IL-6) are elevated in women with PPCM
compared to pregnancy controls [15, 16]. However, these
cytokines are elevated in patients with other cardiomy-
opathies.
ECGabnormalitiesareoftennotedonpresentation,most
commonly sinus tachycardia, nonspeciﬁc ST-T segment
changes, LV hypertrophy, premature ventricular contrac-
tions, and bundle branch block [17]. However, these changes
may be present in a number of disorders as well as normal
states. Moreover, the ECG may demonstrate no signiﬁcant
changes [18].
Evaluation of suspected PPCM should include an
echocardiogram. Average EF at diagnosis is often reported
in the range of 20–30%; however, some women present with
severe systolic dysfunction and an EF <20% [19]. Several
studies have noted a worse prognosis in patients presenting
with an EF <20% or LV end diastolic dimension >6cm
[4, 11]. LV thrombus is present at diagnosis in 17% of
patients and conveys a poor prognosis [19].
Invasive evaluation, such as cardiac catheterization or
endomyocardial biopsy, is often unnecessary for diagnosis
or treatment. The pathology identiﬁed on endomyocardial
biopsy is often nonspeciﬁc edema, inﬂammation, hyper-
trophy, and ﬁbrosis [8]. Inﬂammation consistent with
myocarditis is present in up to 50% of specimens [20, 21].
None of these ﬁndings are speciﬁc for PPCM.
6.Prognosis
Recovery of systolic function occurs in roughly half of
aﬀected women and usually occurs within 6 months of
symptom onset [22]. A rapid recovery of EF is often seen in
patients after initial diagnosis and diuresis [23]. EF > 45%
at 2 months after diagnosis predicts full functional recovery
in 75% of women with this result [19]. However, one recent
study has reported mortality up to two years after diagnosis
despite functional recovery [24]. Of the approximately 50%
of women without full recovery of systolic function, many
beneﬁt from improved EF or functional status, while others
have persistent or progressive systolic dysfunction leading to
transplant or death [1].
7.PotentialEtiologies
A proposed, but unlikely, etiology is nutritional deﬁciency.
Selenium deﬁciency has been investigated given its associ-
ation with heart failure in the third world independent of
pregnancy. Forty percent of women with PPCM had low
levels of selenium, but no correlation was found between
selenium levels and the severity of cardiomyopathy [25].
Another study found no diﬀerence in selenium levels in
patients with PPCM versus control patients [26].
A genetic predisposition is plausible in PPCM; however,
little data exist to conﬁrm this theory. Familial clustering
has been reported [16], and regional distribution is present
in Africa. The genetic predisposition is likely at the cellu-
lar/molecular level, involving either altered cell signaling for
mitochondrialmediatedapoptosis,inﬂammatorymodulator
activation, or altered immune response during pregnancy
leading to infection or autoimmunity. Each of these abnor-
malities being dependent upon pregnancy ﬁts with the
clinical picture of PPCM, a phenotypically normal woman
who develops cardiomyopathy in the setting of pregnancy,
but often recovers normal systolic function postpartum.
Hormonal abnormalities could contribute as women
with PPCM have been found to have lower levels of
progesterone, prolactin, and estrogen during pregnancy,Journal of Pregnancy 3
all hormones with a vasodilatory response preventing
hypertension in the face of intravascular volume expansion
[16]. Whether this ﬁnding is causative or associative is
unclear.
Alterations in the immune response are normal in
pregnancy as immunosuppression is necessary to ensure
the safety of the fetus during development. A potential
maladaptive response to pregnancy which may account for
the development of PPCM is an autoimmune response to
the cardiomyocyte. Antibodies recognizing unique cardiac
tissue proteins have been described in the sera of patients
with PPCM. In this same study, the sera from patients with
other cardiomyopathies did not recognize the same cardiac
tissue proteins [16].
Infectious agents invading the cardiomyocyte resulting
in myocarditis have been described in PPCM. Given the
immunosuppressed state of pregnancy, it is logical that
pregnant women are more susceptible to infection or viral
reactivation. Endomyocardial biopsy specimens from some
patients demonstrate inﬂammatory changes consistent with
myocarditis, as well as the presence of viral DNA in some
patients with PPCM [20, 21, 27]. The exact role of viral
infection or reactivation in the development and clinical
course of PPCM remains unclear, and no convincing evi-
dence exists that myocarditis is the primary etiology of this
disorder. More recently, Sliwa et al. have found no signiﬁcant
diﬀerence in outcome in patients with PPCM infected with
HIV as opposed to those not infected with HIV [24].
The most exciting recent insight into the etiology of
P P C Mi n v o l v e sam o u s em o d e l .F e m a l em i c ew i t had e l e t i o n
of stat3 develop PPCM. Deletion of stat3 results in enhanced
oxidative stress which is associated with the generation of a
16kDa prolactin derivate. This protein appears to be a key
factor in the development of PPCM, leading investigators
to treat patients with bromocriptine with early promising
results [18, 28–30].
8. Treatment
Standard heart failure treatment is recommended for PPCM
until the EF recovers. Medications include angiotensin con-
verting enzyme inhibitors (ACE inhibitors) or angiotensin
receptor blockers (ARBs), beta blockers, and diuretics. How-
ever, caution must be exercised as ACE inhibitors and ARBS
are contraindicated in pregnancy. In addition, patients are
advised regarding nonpharmacologic approaches such as salt
restriction and the avoidance of oﬀending medications (e.g.,
nonsteroidal anti-inﬂammatory drugs). Select patients may
eventually beneﬁt from cardiac resynchronization therapy,
internal deﬁbrillators, or cardiac transplantation. If systolic
function normalizes, patients can discontinue heart failure
medications without subsequent decompensation [19].
An important therapeutic option to consider is antico-
agulation. Pregnancy conveys a hypercoagulable state that
extends approximately 3 months postpartum. During this
time,patientswithPPCManddepressedsystolicfunctionare
at high risk for thrombus formation and thromboembolic
events [9]. Warfarin anticoagulation should be considered
for prevention of morbidity or mortality from thromboem-
bolism [31].
No speciﬁc treatment has been identiﬁed to signiﬁcantly
alter the morbidity of PPCM. Small trials have reported
beneﬁts of pentoxifylline, intravenous immunoglobulin, and
bromocriptine. Pentoxifylline decreased TNFα levels and
increased EF in patients with PPCM [32] although this ﬁnd-
ing has not been reproduced. Intravenous immunoglobulin
(IVIG) improved EF compared to standard treatment in one
small retrospective study of 6 cases compared to 11 controls
[33]. More recently, a 16kDa prolactin derivate has been
causally related in PPCM [28]. Case reports of recovery from
PPCM with bromocriptine treatment have been described
[18, 28–30]. Larger studies will need to be performed to
validate this treatment.
Transplant requirements in small series are reported to
be 6 to 10% [11, 34, 35]. Transplant requirement was his-
torically poor in this group due to more frequent and severe
episodes of rejection, but has improved with advances in the
treatment of rejection and is no diﬀerent from transplant
survival in patients with idiopathic dilated cardiomyopathy
[36]. In patients not receiving transplant, mortality is usually
secondary to progressive systolic dysfunction or sudden
cardiac death, but in up to one third of patients is due to
fatal thromboembolic events [9].
In addition to prescribing standard heart failure
treatment, appropriate management of the patient with
PPCM involves counseling regarding subsequent pregnan-
cies. Women with persistent LV dysfunction are advised not
to pursue further pregnancies. How to advise women with
recovered LV function is more challenging. Some studies
report good outcomes [37], and others report a high rate of
recurrence [11, 38, 39]. A useful tool to help predict those
patients whose LV function has recovered could be stress
echocardiography, reported in a small series [40]. The lack of
contractile reserve on dobutamine stress echocardiography
may predict recurrence of systolic dysfunction in subsequent
pregnancies [40]; however, this ﬁnding has not been investi-
gated in a large series of patients.
9. Summary
Although rare, when a woman is diagnosed with PPCM,
only 50% will be expected to fully recover cardiac function.
Obstetricians should suspect the diagnosis, particularly if
the patient has risk factors, including African-American
ethnicity. Evaluation should include an echocardiogram to
assess the LV systolic function. Treatment includes ACE
inhibitors or angiotensin receptor blockers, beta blockers,
and diuretics. Consideration should be given to anticoagu-
lation. A number of causes are being investigated, including
nutritional, infectious, and genetic, which, hopefully, lead to
more targeted treatments.
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